therapeutic effect of intranasal administration of a eukaryotic expression vector co‐expressing Der p2 and A20 protein (pVAX1‐Der p2‐A20) on mice with allergic rhinitis. The pVAX1‐Der p2‐A20 vaccine was prepared and encapsulated into poly(L‐lactide‐co‐glycolide) (PLGA) nanoparticles. An allergic rhi
HU WENHUI,MA LI,GUI YANG,XIANHAI ZENG,JIANGQI LIU,BAOHUI CHENG,HU TIANYONG,HAILIANG ZHAO,ZHIQIANG LIU
2019-01-01
Abstract:Allergic rhinitis (AR) is a common disease that requires more convenient, safe and effective antigen‐specific immunotherapies. The present study aimed to investigate the therapeutic effect of intranasal administration of a eukaryotic expression vector co‐expressing Der p2 and A20 protein (pVAX1‐Der p2‐A20) on mice with allergic rhinitis. The pVAX1‐Der p2‐A20 vaccine was prepared and encapsulated into poly(L‐lactide‐co‐glycolide) (PLGA) nanoparticles. An allergic rhinitis Balb/c mouse model was established through intraperitoneal sensitization with recombinant Der p2 and cholera toxin followed by intranasal challenge with recom‐ binant Der p2. The treatment effect of the DNA vaccine on nasal allergic inflammation was evaluated, and serum IgE, sIgE, IgG and cytokine levels were determined by ELISA. The percentage of CD4+CD25+Foxp3+Tregs in the spleen was detected by flow cytometry. The DNA vaccine co‐expressing Der p2 and A20 was successfully constructed and encapsulated into PLGA nanoparticles. Der p2‐A20 DNA vaccine intra‐ nasal administration markedly ameliorated Der p2‐induced nasal allergic inflammation. The serum Der p2‐specific IgE, IL‐4 and IL‐13 expression levels were inhibited, while the Der p2‐specific IgG1, IgG2a and IFN‐γ expression levels in the serum and splenic CD4+CD25+Foxp3+Treg population were significantly increased after Der p2‐A20 DNA vaccine treatment. These results indicated that the Der p2‐A20 DNA vaccine alleviates nasal allergic inflammation and promotes splenic Treg population in mice with allergic rhinitis. Introduction Allergic rhinitis (AR) is a non‐infectious nasal mucosal disease caused by the exposure of susceptible individuals to exogenous allergens and the release of IgE‐mediated histamine and other mediators, and it is accompanied by immune cell activation and cytokine secretion (1). As a common otolaryngology disease, the incidence of AR has increased greatly in the past decades (2). AR has become a global public health problem and caused huge economic burden to individuals, families and society. At present, the treatment of AR mainly includes avoid‐ ance of contact with susceptible allergens, anti‐inflammation, antihistamine and other symptomatic treatments, which are far from satisfactory. Allergen‐specific immunotherapy (AIT) is the only WHO approved aetiological treatment for allergic diseases that can effectively change the natural process of AR (3). At present, the clinically used desensitization agents are mainly from allergen crude extracts, which contain complex components, resulting in poor stability, difficulty in standardization, and serious side effects (4). Therefore, it is particularly important to develop new, safe and efficient methods for the prevention and treatment of AR. The dust mite is an important allergen of AR, and studies have revealed that approximately 70‐80% of patients with upper respiratory tract allergy have positive reactions to dust mites, among which Der f2 and Der p2 have the highest serum positive rate (5,6). A20, also known as tumour necrosis factor‐induced protein 3 (TNFAIP3), is a ubiquitin‐modified enzyme protein encoded by the TNFAIP3 gene in the cyto‐ plasm that regulates a variety of immune cell functions and is involved in maintaining immune homeostasis (7). Mutations in the A20 gene are associated with inflammation, allergic disease and tumourigenesis (8). Mice with A20 gene dele‐ tion have severe inflammation and tissue damage, and A20 overexpression improves the tolerance of intestinal mucosa to LPS and enhances the intestinal mucosal barrier function. A20 plays an important role in the pathogenesis of allergic diseases, and its absence can lead to the occurrence of allergic asthma (8). Studies have revealed that a DNA vaccine displays not only immunogenicity and safety but also greater flexibility than previous protein vaccines for its convenient modification and construction (9). Compared with the AIT and recombinant Der p2‐A20 DNA vaccine attenuates allergic inflammation in mice with allergic rhinitis WENHUI HU1,2*, LI MA1*, GUI YANG1, XIANHAI ZENG1, JIANGQI LIU1, BAOHUI CHENG1, TIANYONG HU1, HAILIANG ZHAO1 and ZHIQIANG LIU1 1Department of Otolaryngology, Longgang ENT Hospital and Shenzhen Key Laboratory of ENT, Institute of ENT, Shenzhen, Guangdong 518172; 2Zunyi Medical College, Zunyi, Guizhou 519090 P.R. China Received April 1, 2019; Accepted August 30, 2019 DOI: 10.3892/mmr.2019.10760 Correspondence to: Professor Zhiqiang Liu or Professor Hailiang Zhao, Department of Otolaryngology, Longgang ENT Hospital and Shenzhen Key Laboratory of ENT, Institute of ENT, 3004 Longgang Avenue, Longgang, Shenzhen, Guangdong 518172, P.R. China E‐mail: liuzhiqiang05312438@126.com E‐mail: 825109331@qq.com *Contributed equally